Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)
ID: 351747Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 9, 2024 12:00 AM
  4. 4
    Due May 30, 2024 12:00 AM
Description

The National Institutes of Health is offering a grant opportunity titled "Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)". This grant aims to support small businesses in developing solutions for commercialization that enable regional genomic medicine eConsult services. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The eligible applicants for this grant are small businesses. Non-domestic entities and non-U.S. components of U.S. organizations are not eligible to apply. The grant provides additional information on eligibility criteria. The close date for applications is May 30, 2024. For more information and to apply, visit the following link: Additional Information. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
Files
Title
Posted
4/20/2024
Similar Opportunities
Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)". This grant aims to stimulate innovation and advance understanding of the use and sharing of genomic information and technologies in clinical care. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The funding instrument for this opportunity is a grant, and there is no cost sharing or matching requirement. The maximum award ceiling is $250,000. The deadline for applications is February 11, 2025. For more information and to apply, visit the following link: [Advancing Genomic Medicine Research Grant](http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-033.html).
Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)". This grant aims to stimulate innovation and advance understanding of the use and sharing of genomic information and technologies in clinical care. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and Historically Black Colleges and Universities (HBCUs), among others. The funding instrument for this opportunity is a grant, and there is no cost sharing or matching requirement. The maximum award ceiling is $500,000. The deadline for applications is February 11, 2025. For more information and to apply, visit the following link: [Advancing Genomic Medicine Research Grant](http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-032.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)". This grant is a cooperative agreement in the category of Health. The purpose of this grant is to support small businesses in conducting exploratory clinical trials of investigational agents such as drugs, biologics, surgical therapies, or devices. The trials should contribute to the justification for and provide the data required for designing clinical studies. The diseases chosen for study should align with the NINDS strategic plan and clinical research interests. Small businesses are eligible to apply for this grant, while non-domestic entities and non-U.S. components of U.S. organizations are not eligible. The grant has a maximum award ceiling of $1,000,000. The deadline for application submission is September 5, 2024. For more information and to apply, please visit the following link: [NeuroNEXT Small Business Innovation in Clinical Trials Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-21-224.html). For any further inquiries, please contact the NIH OER Webmaster at grantsinfo@nih.gov.
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)". This grant is specifically for Small Business Concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The purpose of this grant is to support projects that focus on products related to the mission and goals of the NINDS, which may include the evaluation of drugs, biologics, devices, diagnostics, as well as surgical, behavioral, or rehabilitation therapies. Only SBIR Phase II and Fast-Track applications are supported under this program, and SBIR Phase I applications are only accepted as part of a Fast-track application. The grant does not require cost sharing or matching requirements, and it falls under the category of funding activity for Health. The eligible applicants for this grant opportunity are Small Businesses. However, non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. The close date for this grant opportunity is September 5, 2026, and the last updated date was November 27, 2023. The archive date for this grant is October 11, 2026. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html). Any additional inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)". This grant is part of the Income Security and Social Services category of funding activity and falls under the Grant funding instrument type. Small businesses are eligible to apply for this grant. The purpose of this grant is to invite eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. The NIH is seeking small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components. The grant requires the proposal of at least 1 clinical trial, and the proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. For more information and to apply, interested applicants can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PA-24-248.html](http://grants.nih.gov/grants/guide/pa-files/PA-24-248.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.